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A B S T R A C T   
Introduction: Secondary lymphoedema of the extremities is an important quality-of-life issue for patients who 
were treated for their malignancies. Indocyanine green (ICG) fluorescent lymphography may be helpful for 
assessing lymphoedema and for planning lymphaticovenular anastomosis (LVA). The objective of the present 
clinical trial is to confirm whether or not ICG fluorescent lymphography using the near-infrared monitoring 
camera is useful for assessing the indication for LVA, for the identification of the lymphatic vessels before the 
conduct of LVA, and for the confirmation of the patency of the anastomosis site during surgery. 
Methods and analysis: This trial is a phase III, multicentre, single-arm, open-label clinical trial to assess the ef-
ficacy and safety of ICG fluorescent lymphography when assessing and treating lymphoedema of patients with 
secondary lymphoedema who are under consideration for LVA. The primary endpoint is the identification rate of 
the lymphatic vessels at the incision site based on ICG fluorescent lymphograms obtained before surgery. The 
secondary endpoints are 1) the sensitivity and specificity of dermal back flow determined by ICG fluorescent 
lymphography as compared with 99mTc lymphoscintigraphy—one of the standard diagnostic methods and 2) the 
usefulness of ICG fluorescent lymphography when confirming the patency of the anastomosis site after LVA. 
Ethics and dissemination: The protocol for the study was approved by the Institutional Review Board of each 
institution. The trial was filed for and registered at the Pharmaceuticals and Medical Devices Agency in Japan. 
The trial is currently on-going and is scheduled to end in June 2020. 
Trial registration number: jRCT2031190064; Pre-results.   
1. Introduction 
Secondary lymphoedema of the extremities is an important quality- 
of-life issue for patients who were treated for their malignancies [1,2]. 
Lymphoedema is generally difficult to treat, and conservative treatment 
is the main treatment [3,4]. 99mTc lymphoscintigraphy has been used for 
many years as one of the standard diagnostic methods of lymphoedema 
and is currently covered by the national health insurance of Japan [5–7]. 
However, lymphoscintigraphy has the following disadvantages: high 
costs, large-sized equipment for examination, low resolution, and radi-
ation exposure. 
Since 2007, fluorescent lymphography with indocyanine green (ICG) 
for assessing lymphoedema has been introduced [8–25]. ICG fluorescent 
lymphography has been reported as a potentially useful assessment 
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method to depict the lymphatic vessels in real time and to assess their 
function at low cost. ICG fluorescent lymphography allows the moni-
toring of time-course changes in the morphology and function of the 
lymphatic vessels and can be conducted anywhere including the ex-
amination and operation rooms [8–12]. A retrospective study showed a 
significant correlation in lymphoedema severity between ICG fluores-
cent lymphography and lymphoscintigraphy [10]. The usefulness of 
lymphaticovenular anastomosis (LVA) is well recognized among 
lymphatic microsurgeons, and ICG fluorescent lymphography has 
evolved as a reliable assessment method of extremity lymphoedema. In 
recent years, the usefulness of LVA that improves lymphatic flow has 
been reported [26–28]. 
ICG fluorescent lymphography using the near-infrared monitoring 
camera utilizes the following properties: 1) ICG is excited by irradiating 
the near-infrared ray of 760 nm in wavelength, and fluorescence of 830 
nm in wavelength is thus generated; and 2) ICG, which was injected 
subcutaneously, is mostly bound to albumin and is then incorporated 
and delivered into the lymphatic vessels [8]. The use of the near-infrared 
monitoring camera permits the demonstration of the current direction of 
ICG in the lymphatic vessels and of the regurgitation of the lymphatic 
valves, thus allowing the depiction of dermal back flow—a finding 
characteristic of lymphoedema. Furthermore, the camera quite excels in 
allowing the real-time confirmation of lymph dynamic. Some studies 
reported a significant correlation between pathological stages deter-
mined by 99mTc lymphoscintigraphy and ICG fluorescent lymphog-
raphy; however, the ICG findings appropriate for LVA have not been 
standardized [10–12]. 
ICG fluorescent lymphography is expected to help the appropriate 
selection of patients with lymphoedema who are indicated for LVA, to 
serve for the identification of the lymphatic vessels before and during 
surgery and for the confirmation of the patency of the anastomosis site, 
and to greatly contribute to an improvement in the therapeutic out-
comes of patients with lymphoedema; however, all of them need to be 
investigated in a prospective clinical study. 
The objective of the present clinical trial is to confirm whether or not 
ICG fluorescent lymphography using the near-infrared monitoring 
camera is useful for specifying patients to whom LVA is indicated, for 
lymphatic vessel identification before the conduct of LVA, and for the 
confirmation of anastomosis site patency during surgery. 
2. Methods 
2.1. Trial design 
The present clinical trial is a multicentre, collaborative, confirma-
tory, single-arm, open-label study. All patients with secondary lym-
phoedema in the lower or upper extremities, who are under 
consideration for LVA at the participating institutions, will receive 
written and oral information about the HArmonised Medical Assessment 
of lyMphoedemA based on The diagnoStic Usefulness of fluorescent 
lymphography with IndoCyanine Green (HAMAMATSU-ICG) study. 
In this study, the primary endpoint can be verified only in patients 
with radiographic evidence of lymphostasis and the presence of the 
anastomosable lymphatic vessels, who are candidates for LVA. There-
fore, patients who meet the inclusion criteria and do not fall under any 
of the exclusion criteria for this study should receive investigational 
drugs after registration to assess the presence of lymphedema and 
anastomosable lymphatics. Two types of registration are established in 
this study: the primary registration—the registration of patients to be 
conducted at the onset of the assessment phase; and the secondary 
registration—the registration of patients to be conducted at the onset of 
the treatment phase. After the primary registration, patients should be 
evaluated in the assessment phase, and those who meet the inclusion 
criteria and do not fall under any of the exclusion criteria for the sec-
ondary registration should be evaluated in the treatment phase. Patients 
who meet the eligibility criteria for primary registration should undergo 
ICG fluorescent lymphography and 99mTc lymphoscintigraphy. LVA 
should not be conducted for ineligible patients among them, and the 
present study should be discontinued for the former. Patients who meet 
the eligibility criteria for secondary registration will undergo preoper-
ative and intraoperative ICG fluorescent lymphography. The trial 
outline is schematised in Fig. 1. 
2.2. Eligibility criteria 
A patient, who meets all of the following conditions, should be 
subject to the primary registration: 1) who was diagnosed with sec-
ondary lymphoedema of the extremities based on clinical symptoms; 2) 
who was diagnosed with stage I to II lymphoedema from their clinical 
symptoms as defined by the International Society of Lymphology, which 
was categorized from stage 0-III; 3) who was 20 years of age or older at 
the time of informed consent acquisition; and 4) who gave his/her free 
will-based written informed consent after receiving a sufficient expla-
nation prior to enrollment in the present clinical trial and based on a 
sufficient understating about the present clinical trial. 
A patient, who falls under any of the following conditions, should not 
be subject to the primary registration: 1) who has primary lymphoe-
dema; 2) who has allergy against iodine; 3) who has shown shock caused 
by ICG administration in the past; 4) who has shown symptoms of al-
lergy caused by 99mTc administration in the past; 5) who has allergy 
against xylocaine; 6) who is lean (body mass index [BMI]: <18 kg/m2) 
or obese (BMI: > 30 kg/m2); 7) who is a woman being pregnant, being 
breast-feeding, or willing to become pregnant during the study period; 
8) who was otherwise considered inappropriate for enrollment in the 
clinical trial by the investigator; or 9) who has lymphoedema in both the 
upper and lower extremities, thus not allowing limitation to either the 
upper or lower extremities. 
A patient, who meets all of the following conditions, should be 
subject to the secondary registration: 1) in whom the site of linear 
pattern was confirmed by ICG fluorescent lymphography after the pri-
mary registration; and 2) who was diagnosed with lymphoedema by 
99mTc lymphoscintigraphy after the primary registration. 
A patient, whose ICG fluorescent lymphograms fall under any of the 
following conditions, should not be subject to the secondary registra-
tion: (1) in whom the linear pattern cannot be confirmed because of 
presenting only the “area of dermal back flow pattern that is indicative 
of the reversed current of the collecting lymphatic vessels into the skin” 
and the “area where a fluorescent lymphogram is not found at all,” 
which led to the judgment that the lymphatic vessels are difficult to 
identify; (2) who was otherwise judged to be inappropriate as a subject 
to the present trial; (3) who has had symptoms of allergy caused by the 
subcutaneous injection of ICG; or (4) who was diagnosed to have 
oedema due to causes other than lymphoedema because of presenting 
normal lymphoscintigraphic findings. 
2.3. Recruitment 
This trial was filed for and registered at the Pharmaceuticals and 
Medical Devices Agency (PMDA) in June 2019. Recruitment started in 
July 2019 and was completed in March 2020 because 55 patients were 
registered, which exceeded the target number of 50 patients with lym-
phoedema for the secondary registration. This study is being conducted 
at 4 university hospitals in Japan. 
2.4. Sample size calculation 
None of previous articles refer to the identification rates of the 
lymphatic vessels in patients with lymphoedema when conducting and 
not conducting ICG fluorescent lymphography. A multicentre clinical 
trial of ICG on sentinel lymph node biopsy in patients with breast cancer 
was designed to indicate its efficacy at a lymph vessel identification rate 
of 90%. Consequently, the lymph vessel identification rate was 99.6% 
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[26]. 
ICG should be considered useful when the positivity rate is 90%. The 
target number of patients for the present clinical trial was calculated to 
be 118, when assuming a threshold of 80% and an expected value of 
90% (90% power, 5% two-sided significance level). 
Usually, LVA is conducted at 5 or more sites of an extremity. To avoid 
verifying the accuracy of lymphatic vessel identification several times 
for the same lymphatic vessels in a certain area, the extremity is divided 
into 4 areas and the number of examinations in each area is limited. 
Verification is expected to occur in 3 or more sites on average, and any 
upper limit is not established for the points to verify the accuracy of 
lymph node identification as long as the protocol is followed. The target 
number of patients with lymphoedema for the secondary registration, 
which is good enough to examine 150 sites, should be set at 50. 
2.5. Interventions 
ICG fluorescent lymphography should be conducted to achieve the 
following objectives according to the schedule for 3 active study visits: 
2.5.1. ICG fluorescent lymphography to assess lymphoedema in the ICG 
administration phase [assessment phase] after the primary registration 
1) Local anaesthesia with 0.5% xylocaine should be conducted before-
hand at the planned site for ICG subcutaneous injection. The 2.5 mg/ 
mL ICG solution (Diagnogreen®, 25 mg: Daiichi Sankyo Co., Ltd, 
Japan) should be injected subcutaneously to the right and left, upper 
or lower extremities. The target extremities should include 5 sites per 
extremity (upper extremities: the second interdigit, the fourth 
interdigit, the distal three-fourths point on the straight line that 
connects the distal end of the radial styloid process and the head of 
the first metacarpal bone, the distal end of the ulnar styloid process, 
and the distal forearm at the level of the tendon for long palmar 
muscle; and lower extremities: the first interdigit, the fourth inter-
digit, below the medial malleolus, below the lateral malleolus, and 
the midpoint on the straight line that connects the head of the fifth 
metatarsal bone and the lateral malleolus (Fig. 2) [27]. The 2.5 
mg/mL ICG solution, 0.2 mL per site, should be injected 
subcutaneously.  
2) With the patient on bed who is in the supine position and at rest and 
under indoor illumination that is reduced immediately after subcu-
taneous injection, the near-infrared monitoring camera (Pde-neo®, 
Hamamatsu Photonics K⋅K., Japan) will be used to monitor and re-
cord the imaging findings on the extremity surface. Regarding the 
lower extremities as well, recording should be conducted with the 
patient in the prone position. ICG, which is retained in the hypo-
dermis, should be drained manually to quickly confirm the course of 
the collecting lymphatic vessels. ICG fluorescent lymphograms can 
be categorized to the following regions: A) the region of linear 
pattern where the pre-collecting lymphatic vessels or collecting 
lymphatic vessels are depicted in a linear pattern; B) the region of 
dermal back flow pattern where the reversed current of lymph of the 
collecting lymphatic vessels into the skin is obvious; and C) the re-
gion where any fluorescent image cannot be seen at all (Fig. 3). The 
image should be obtained immediately after injection. In patients in 
whom findings in the entire extremities cannot be obtained imme-
diately after injection due to the slow movement of ICG, imaging 
should be conducted again at a later time without reinjection, and 
the time from injection to reimaging is recorded. However, the check 
of the findings should be completed not later than 3 h after injection. 
3) 99mTc lymphoscintigraphy using the injection solution of a radio-
pharmaceutical agent, standard human serum albumin diethylene-
triamine pentaacetic acid technetium (99mTc) (Poolscinti® 
Injectable), should be conducted in all patients who were included in 
the primary registration within 8 weeks after ICG fluorescent 
lymphography in order to determine the sensitivity and specificity of 
lymphoedema diagnosis by ICG fluorescent lymphography when 
considering 99mTc lymphoscintigraphy as one of the standard diag-
nostic methods. 99mTc lymphoscintigraphy should be conducted at 
120 min after radioisotope administration. 
Fig. 1. Diagram of the study outline. ICG, indocyanine green; LVA, lymphaticovenular anastomosis. (For interpretation of the references to colour in this figure 
legend, the reader is referred to the Web version of this article.) 
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2.5.2. Fluorescent ICG lymphography before surgery to identify the 
lymphatic vessels in the investigational drug administration phase [treatment 
phase] after the secondary registration 
1) Local anaesthesia with 0.5% xylocaine should be conducted before-
hand at the planned sites for ICG subcutaneous injection. ICG should 
be injected subcutaneously to the extremity where LVA is intended. 
The target extremities should include 5 sites per extremity (Fig. 2). 
The 2.5 mg/mL ICG solution, 0.2 mL per site, should be injected 
subcutaneously. 
2) With the patient on bed who is in the supine position after subcu-
taneous injection, a red pen should be used to mark the skin on the 
confirmed fluorescent lymphograms of linear pattern.  
3) The incision site for LVA should be determined at the site where the 
linear pattern was found. The depicting ability of ICG is estimated to 
differ depending on the thickness of the skin and subcutaneous adi-
pose tissue. Therefore, 4 areas should be established in distal-to- 
proximal order in both the upper and lower extremities (Fig. 4). 
The maximal number of skin incision sites for lymphatic vessel 
dissection should be 2 to avoid the repeated identification of the 
same lymphatic vessels in the same region. Furthermore, the skin 
incision site for research in the same area should be one for the 
continuing linear pattern. This arrangement is to avoid the mutual 
influences among multiple sites of anastomosis and to ensure their 
independency. The length of skin incision should be determined in 
response to the thickness of subcutaneous fat, ranging from 0.5 cm to 
2.0 cm. Surgery should be conducted under general or local anaes-
thesia. The camera for visible light should be used to photograph and 
record the findings as to whether the anastomosable collecting 
lymphatic vessels are successfully identified in reality on the line of 
skin incision that was set before surgery (Fig. 5). 
Fig. 2. Five sites for ICG injection: (A) hand and (B) foot ICG, indocyanine green. (For interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
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2.5.3. ICG fluorescent lymphography during surgery to check the patency of 
the anastomosis site after LVA in the investigational drug administration 
phase [treatment phase] 
LVA should be conducted in the case that the veins appropriate for 
LVA were confirmed in the periphery of the identified lymphatic vessels. 
After anastomosis, the surgeon should judge (a) patency, (b) non-
patency, or (c) unclearness according to the conventional methods: (1) 
visual confirmation of the movement of lymph or blood at the anasto-
mosis site; and (2) examination of patency—a method by which 2 
tweezers are used to transiently generate a fluid-free condition between 
the tweezers by stemming the venous flow with them, followed by the 
confirmation of fluid movement at the anastomosis site after lifting only 
the tweezer that was placed on the peripheral side. After confirmation 
according to the conventional methods, the surgeon should subcutane-
ously inject 0.2 mL of ICG 2.5 mg/mL solution into the site distal from 
each anastomosis site and should judge (a) patency, (b) nonpatency, or 
(c) unclearness based on the findings of ICG fluorescent lymphography. 
The schedule for the study visits and data collection is summarized in 
Table 1. 
3. Outcomes 
3.1. Primary endpoint 
The primary endpoint of this study is to calculate the identification 
rate of the lymphatic vessels at the incision site only in patients who are 
indicated for LVA based on the following requisites: the radiographic 
evidence of lymphatic stasis; and the presence of the anastomosable 
lymphatic vessels. Therefore, the investigational drug should be 
administered in the primary and secondary registration. Patients who 
meet the eligibility criteria for the primary registration will be assessed 
in the assessment phase and will undergo ICG fluorescent lymphography 
and lymphoscintigraphy. LVA will not be conducted for those whom the 
procedure is not indicated, and the study will be discontinued. 
Furthermore, patients who meet the eligibility criteria for the secondary 
Fig. 3. ICG fluorescent lymphograms can be categorized to the region of linear 
pattern, the region of dermal back flow pattern, and the region where any 
fluorescent image cannot be seen at all. (A): Linear pattern, (B): Dermal back 
flow pattern.ICG, indocyanine green. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the Web version of 
this article.) 
Fig. 4. Both the upper and lower extremities were divided into the following 4 
areas—lower extremities: 3 borders established at 6 cm proximal from the 
centre of the medial malleolus, 4 cm distal from the popliteal fossa, and 4 cm 
proximal from the popliteal fossa; and upper extremities—3 borders established 
at 6 cm proximal from the ulnar styloid process, 4 cm distal from the cubital 
fossa, and 4 cm proximal from the cubital fossa. 
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registration will be assessed in the treatment phase and will undergo 
preoperative and intraoperative ICG fluorescent lymphography. The 
third-party expert panel independent from the present clinical trial 
should make the final judgment based on the triad of fluorescent lym-
phograms before surgery, light images before surgery, and the photo-
graphs of the lymphatic vessels that were taken after skin incision during 
surgery. 
3.2. Efficacy secondary endpoints  
(1) Sensitivity and specificity of ICG lymphography for specifying 
patients to whom LVA is indicated when using 99mTc lympho-
scintigraphy as one of the standard diagnostic methods 
The specification of patients with lymphoedema for LVA should be 
judged based on the findings of 99mTc lymphoscintigraphy and ICG 
fluorescent lymphography at the time of assessing the disorder, and the 
sensitivity and specificity of ICG lymphography when using 99mTc 
lymphoscintigraphy as one of the standard diagnostic methods should 
be calculated from the results of the examinations. In this study, the 
anatomy of the lymphatic vessels on the contralateral side of the affected 
arm of unilateral breast cancer patients should also be assessed ac-
cording to the same assessment criteria as those for the affected side 
because breast cancer patients with unilateral lymphoedema often 
present the lymphatic dysfunction of the contralateral “unaffected” arm 
[28]. 
The criteria for the indication of LVA based on 99mTc lymphoscinti-
graphic findings: the case in which the lymphatic vessels of the auxiliary 
lymph nodes in the upper extremities and of the inguinal lymph nodes in 
the lower extremities are not depicted or depicted just unclearly, as well 
as dermal back flow was depicted in the extremities (categorized to 
types II, III, and IV according to the classification of Maegawa et al.); the 
case in which the movement of the tracer from the injection site cannot 
be found (categorized to type V according to the classification of Mae-
gawa et al.); and the case in which another atypical dermal back flow is 
depicted (corresponding to unclassifiable according to the classification 
of Maegawa et al.) [12,13] Lymphedema in the status of surgical indi-
cation should be recorded as “negative” in other cases. 
The criteria for the indication of LVA based on 99mTc ICG fluorescent 
lymphographic findings: the case in which obvious dermal back flow is 
found in the extremities, and the case in which any movement of ICG 
from the injection site cannot be found. In this study, the splash pattern 
of lymphoedema—which has not necessarily been reported as a sign of 
irreversible chronic lymphoedema—should not considered as an 
indication for LVA. 
LVA should not be indicated when the target extremity consists of 
only the region of the linear pattern and the area where a fluorescent 
image is not found. 
The above should be based to calculate the sensitivity and specificity 
of the ability of ICG fluorescent lymphography to determine lymphoe-
dema for LVA when using lymphoscintigraphy as one of the standard 
diagnostic methods. 
The third parties, who are specialists in the surgical treatment of 
lymphoedema outside the study site, should judge centrally that the 
images of 99mTc lymphoscintigraphy and ICG fluorescent lymphography 
are positive or negative for patients to whom LVA is indicated, 
respectively.  
(2) The outer diameter of the identified lymphatic vessels (the 
number of the overlapped lymphatic vessels and the outer 
diameter of the respective vessels), as well as the distance from 
the skin surface to the lymphatic vessels (during surgery)  
(3) Usefulness of ICG fluorescent lymphography when examining the 
presence or absence of the patency of the anastomosis site during 
LVA (during surgery) 
By using the conventional methods and ICG fluorescent lymphog-
raphy, the surgeon should judge whether or not the latter successfully 
determined the presence or absence of LVA site patency according to the 
following 4-level criterion:  
(a) very useful: the case in which the judgment according to the 
conventional methods does not coincide with the judgment by 
ICG lymphography, with the determination that the judgment by 
ICG lymphography is correct;  
(b) useful: the case in which the judgment by ICG lymphography 
coincided with the judgment according to the conventional 
methods when the judgment according to the conventional 
method indicated patency or nonpatency;  
(c) not much useful: the case in which the judgment by ICG 
lymphography coincided with the judgment according to the 
conventional methods when the judgment according to the con-
ventional methods indicated unclearness; and  
(d) not useful at all: the case in which the judgment according to the 
conventional methods does not coincide with the judgment by 
ICG lymphography, with the determination that the judgment 
according to the conventional methods is correct. 
Fig. 5. (A): ICG fluorescent lymphogram of the forearm and (B): an image of the same region under visible light. The skin incision site was determined preoperatively 
on the linear pattern of an ICG fluorescent lymphogram. (C): A photograph under visible light should be used to confirm whether the anastomosable collecting 
lymphatic vessels are successfully identified in reality on the line of skin incision. 
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3.3. Safety secondary endpoints 
Presence or absence of adverse events and defects. 
3.4. Data management, monitoring, safety and auditing 
In collecting the data, the investigator should prepare the case report 
form by using software that meet the requirements in 21 CFR Part 11, 
Ministerial Ordinance GCP, and ER/ES guideline. 
In the quality control of the clinical trial, the monitor should conduct 
the source document verification as appropriate and should confirm that 
the present clinical trial is conducted in compliance with the procedures 
on the medical institution’s operations related to the present clinical 
trial, the latest protocol, and GCP. 
To assure that the clinical trial was conducted appropriately, as well 
as the preparation, recording, and reporting of data were made appro-
priately in compliance with the protocol and GCP, an auditor who is 
independent from the departments related to the clinical trial including 
the department in charge of monitoring should conduct an audit at the 
medical institution and other facilities related to the conduct of the 
clinical trial and should confirm that quality control is conducted 
appropriately. 
4. Statistical methods 
The primary analysis set for the present clinical trial will be the full 
analysis set (FAS). Out of patients who should be included during the 
secondary registration, those falling under any of the following exclu-
sion criteria will be excluded from the analysis: patients who severely 
violate the protocol; and patients whose images are of poor quality and 
cannot be interpreted (cases of test failure).  
(1) Primary endpoint: the identification rate of the lymphatic vessels 
at the incision site based on ICG fluorescent lymphography 
(positive predictive rate). To date, no previous clinical study has 
mentioned the identification rate of the lymphatic vessels in the 
subcutaneous tissue. A multicentre collaborative confirmatory 
clinical trial of the sentinel lymph node biopsy for breast cancer 
Table 1 
Schedules for the conduct of the clinical trial. The schedules to conduct monitoring, testing, and assessment are shown in the table below. The investigator or sub-





Investigational drug administration 
















Scintigraphy Testing and treatment 
phase (hospitalization and 
control) 
Visit Day 1 
Weeks   26 to   9 
Visit Day 2 
Weeks   17 to   9 
Visit Day 3 










Allowable range – – * þ1 – �1 þ3 
Written informed consent ●        
Primary registration  ●       
Secondary registration    ●     
History taking of the subject’s 
background  
●       
History taking of the primary disease, 
anamnesis, and complications  
●       
Measurement of vital signs  ● ● ● ● ● ● ● 
Blood sampling (hematology, blood 
chemistry)b  
●     ● ● 
Physical examination (measurement of 
the circumference of the upper or lower 
extremities of both sides)  
●     ● ● 
Urinalysis  ●       
Pregnancy testc  ●       
Diagnostic ICG fluorescent 
lymphangiography   
●      
99mTc lymphoscintigraphy (the 
extremities of both sides)    
●     
Photography of appearance  ●       
Classification of International Society of 
Lymphology stages  
●       
ICG fluorescent lymphangiography before 
surgery     
●    
ICG fluorescent lymphangiography 
during surgery (examination of 
patency)      
●   
Monitoring of adverse eventsd   ● ● 
Check of defects   ● ● 
Check of concurrent drugs and concurrent 
therapies  
● ●  
a Visit Day 3 (day of scintigraphy) should be the same day as visit Day 2 (day of ICG lymphangiography) or within 8 weeks. 
b Hematology: WBC, RBC, Hb, Hct, Plt, differential leukocyte counts (neutrophils, lymphocytes, monocytes, basophils, and eosinophils), and prothrombin time 
Blood chemistry: AST, ALT, ALP, γ-GTP, LDH, T-Bil, D-Bil, TP, Alb, Glu, T-Cho, HDL, TG, UA, BUN, Cre, Na, K, Cl, ChE, and HbA1c. 
c Not required for patients about whom the potential of pregnancy can be denied (e.g., women who underwent hysterectomy and menopausal women). 
d All of adverse events, which occurred from the first subcutaneous injection of ICG in the investigational drug administration phase [assessment phase] to the 
completion of the trial period (Day 7). 
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was designed to consider a lymph vessel identification rate of 
90% as being effective [26]. This was based on the fact that prior 
studies had reported a lymph node identification rate of 93%. The 
identification rate in the lymph node biopsy of breast cancer was 
99.6% with respect to the investigational drug alone. The devi-
ation of the lymph flow from normal anatomy is anticipated in 
the present clinical trial. However, a positive predictive rate of 
90% should be established as the primary endpoint because an 
identification rate of 90% is required for demonstrating the use-
fulness of the study. In this study, the positivity rate and the 
Clopper-Pearson 95% confidence interval should be calculated. It 
should be confirmed that the positive rate is at least 90% and the 
lower confidence limit is at least 80%. 
(2) Secondary endpoint-1: usefulness of ICG fluorescent lymphog-
raphy in determining the indication for LVA to examine second-
ary lymphoedema. The usefulness of ICG fluorescent 
lymphography should be assessed as compared with 99mTc lym-
phoscintigraphy—one of the standard diagnostic methods. Fac-
tors such as sensitivity, specificity, positive predictive rate, 
negative predictive rate, positive likelihood ratio, negative like-
lihood ratio, and accuracy should be calculated with an 
assumption that both the sensitivity and specificity of the 
lymphoscintigraphy-based judgement of lymphoedema are 1.0. 
Analyses should be made by using the standard 2 � 2 contingency 
table (lymphoedema positive, lymphoedema negative). The ac-
curacy of the judgement of indication for LVA by ICG fluorescent 
lymphography should be defined as (the number of true positive 
patients þ the number of true negative patients)/(the number of 
false positive patients þ the number of false negative patients). 
(3) Secondary endpoint-2: usefulness of ICG fluorescent lymphog-
raphy in confirming the patency of the anastomosis site after 
LVA. The proportion of patients in whom ICG fluorescent 
lymphography was useful for identifying the presence or absence 
of patency after LVA.  
(4) Presence or absence of adverse events and defects. The incidences 
and 95% confidence intervals of all adverse events and defects in 
the safety analysis population should be calculated. The Clop-
per–Pearson method should be used to calculate confidence in-
tervals. Serious adverse events should be tabulated according to 
patients, and the incidences should be calculated according to 
system organ classes and preferred terms. 
5. Ethics and dissemination 
5.1. Research ethics approval and protocol amendments 
Prior to the conduct of the present clinical trial, the trial will be 
approved by the institutional review board (IRB) at each of the 
participating institutions and will be conducted in accordance with GCP 
principles and the Declaration of Helsinki. The trial was notified and 
registered at PMDA and at the JMACCT registry (RCT2031190064). 
5.2. Patient and public involvement 
Patients of the public will be involved in the design and conduct of 
this trial. Once the trial has been published, participants will be 
informed of the results in a study newsletter suitable for a nonspecialist 
audience. 
5.3. Informed consent 
All participants will receive adequate information on the nature, 
purpose, possible risks and benefits of the trial, and alternative thera-
peutic choices, using the informed consent form approved by the IRB. 
The participants will be given ample time and opportunity to ask 
questions and to consider participation in the trial. 
5.4. Confidentiality 
To assure confidentiality, trial participants will be allocated a unique 
trial identification number throughout the trial. 
6. Discussion 
The usefulness of ICG fluorescent lymphography is well recognized 
among lymphatic microsurgeons because the imaging procedure was 
epoch-making for visualizing the lymphatic vessels that had been un-
observable on the body surface without using a highly invasive method 
[8–25]. Therefore, the need to objectively demonstrate the usefulness of 
ICG fluorescent lymphography in a prospective study has not been dis-
cussed. In recent years, however, new techniques (e.g., magnetic reso-
nance imaging, ultrahigh-frequency ultrasound, and photoacoustic 
lymphography) have been reported. Hence, further improvements in the 
lymphatic vessel-depicting ability of these imaging modalities will be 
required in the future [29–31]. Whether ICG fluorescent lymphography, 
which is already in widespread use among lymphatic microsurgeons, is 
useful in identifying the lymphatic vessels suitable for LVA should be 
investigated in a prospective study before further research examines the 
usefulness of other new modalities in this regard. This clinical study is 
intended not to determine the depiction limits of ICG fluorescent 
lymphography but to record the thickness and depth of the lymphatic 
vessels for reference. Lymphatic flow on ICG fluorescent lymphograms is 
difficult to quantify. Although the doses and dosing concentrations of 
ICG have not been consistently reported in previous clinical studies, the 
results of a questionnaire-based survey—conducted through the Japan 
Society of Plastic Surgeons—at major medical institutions in Japan that 
are engaged in LVA were used for reference. Any adequate studies on the 
lymph vessel identification of the extremities were not available when 
determining the sample size of the present study. Therefore, the lymph 
vessel identification rate in a study on the sentinel lymph node biopsy of 
breast cancer [26] was used for reference. The PMDA admitted the 
above method to determine the sample size of this phase III clinical trial. 
This trial does not consider the quantitative nature of the lymph flow 
velocity measurement [32]. Therefore, we standardized neither the 
location of the injection sites, nor monitoring time between ICG fluo-
rescent lymphography and 99mTc lymphoscintigraphy. The most 
appropriate protocol for 99mTc lymphoscintigraphy in the literature has 
yet to be validated. The protocol of the present study was prepared based 
on the article published by one of the coauthors [7]; the article had 92 
citations as of October 3, 2019, and forms the cornerstone for many 
clinical studies. In the present study, the number of injection sites is 
limited to 2 and scintigraphy is recommended to conduct at 120 min 
after tracer administration based on the review outcomes of patients 
with advanced lymphoedema. 
ICG fluorescent lymphography, which allows the real-time moni-
toring of the lymphatic vessels in the examination room, is highly 
beneficial for both physicians and patients. Hence, the fact that ICG 
fluorescent lymphography causes less burdens and is less time- 
consuming to depict the lymphatic vessels than 99mTc lymphoscintig-
raphy is of clinical relevance. Therefore, we did not use a fixed mea-
surement time protocol for ICG fluorescent lymphography. Five 
injection sites for ICG fluorescent lymphography are presumably most 
efficient for identifying the lymphatic vessels based on a co-authors’ 
study in which lymphangiosomes in cadavers were scrutinized by ICG 
fluorescent lymphography [27]. These 5 sites are supposedly necessary 
to find, at the highest probability rate, the linear pattern of lymphoe-
dema on ICG fluorescent lymphograms that can be used in LVA. Since 
99mTc lymphoscintigraphy is not intended to identify the individual 
lymphatic vessels, it is not useful to inject a radioisotope into these 5 
sites in order to increase radiation exposure. 
This study has several limitations. First, this study is intended to 
examine patients who are indicated for the surgical treatment of sec-
ondary lymphoedema and does not aim to examine patients about whom 
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the cause of lymphoedema was determined (e.g., patients with venous 
disease or suspected primary lymphoedema). Since the primary 
endpoint of this study is to calculate the lymphatic vessel identification 
rate in LVA, we will enroll patients who are scheduled to undergo LVA 
based on their clinical findings. Patients, in whom venous disease is the 
primary cause of lymphoedema, should be excluded from this study 
because LVA is not indicated for them. In addition, the usefulness of LVA 
for patients with primary lymphoedema has not been proved. We will 
intend to examine the usefulness of ICG fluorescent lymphography in 
differentiating lymphoedema caused by lymphatic and venous diseases 
once the results from this study are obtained. Second, the present study 
is designed neither to provide the long-term outcomes of LVA, nor to 
verify the safety of LVA. Any conclusive and globally acceptable views 
are still not obtained with respect to its superiority to therapeutic mo-
dalities including conservative therapy for lymphoedema and to its 
applicability, constituting a great clinical challenge to be addressed 
[33–35]. The present clinical study is intended to preliminarily verify 
the usefulness of ICG fluorescent lymphography in assessing secondary 
lymphoedema and to determine the accuracy of depicting the collecting 
lymphatics and dermal back flow—an indication for LVA. We expect the 
present study be a foundation for future clinical studies to assess the 
surgical treatment of secondary lymphoedema. Third, patients with 
subclinical lymphoedema are excluded from the present study although 
the prophylactic treatment of and surgical intervention for them have 
been reported [15,36]. Since the severity of lymphoedema—based on 
which LVA is indicated for patients with subclinical lymphoede-
ma—remains to be determined, which causes a dispute. Therefore, this 
study aims to examine patients with lymphoedema who show dermal 
back flow—a common indication for surgery. Fourth, 2 sessions of ICG 
fluorescent lymphography, one each in the assessment and treatments 
phases, and should be separated by an interval of at least 8 weeks to 
avoid the effects of residual ICG. On the other hand, the interval between 
ICG fluorescent lymphography and 99mTc lymphoscintigraphy in the 
assessment phase should be shorted to the extent possible. We consider 
that the � 8-week-interval of ICG fluorescent lymphography and 99mTc 
lymphography in the assessment phase is acceptable because the present 
study enrolls patients with chronic lymphoedema of the extremities who 
are undergoing conservative therapy. In the case that significant 
changes (e.g., the disappearance of the linear pattern of lymphoedema 
on ICG fluorescent lymphograms in the treatment phase) occurred, we 
will analyze the relevant changes in a short interval. 
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